

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A02/2016 OS PC

DISPATCHED ON 02ND FEBRUARY 2016

HLA PHENOTYPE OF BLOOD DONOR: HLA-A2, A29; B44, B62; Cw9, Cw16; DR1, DR15; DQ5, DQ6

	Summary of Results							
	PBL/T-Cells				B-Cells			
Total tested	32	32	31	32	24	21	23	24
Positive	0	3	5	24	0	9	18	20
Negative	32	29	26	8	24	12	5	4
NT/Equivocal	1	1	2	1	1	4	2	1
% Positive	0.0%	9.4%	16.1%	75.0%	0.0%	42.9%	78.3%	83.3%
% Negative	100.0%	90.6%	83.9%	25.0%	100.0%	57.1%	21.7%	16.7%
Consensus	Negative	Negative	Negative	Positive	Negative	Not Assessed	Positive	Positive
HLA Antibody Specificity	DR17+	Cw4, Cw6	B14+	B8,B44,DR5,DR8 DR13	DR17+	Cw4, Cw6	B14+	B8,B44,DR5,DR8 DR13

(Defined By CDC)

Lab No.	PBL/T Cell Assessment	B Cell Assessment	Without DTT				Without DTT				Comments
			Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
112	YES	NO	Negative	Positive	Positive	Positive					
119	YES	NO	Negative	Negative	Negative	Positive					
120	YES	YES	Negative	Negative	Negative	Positive	Negative	Positive	Positive	Positive	
128	YES	NO	Negative	Negative	Negative	Positive					
139	YES	YES	Negative	Negative	Negative	Positive	Negative	Equivocal	Positive	Positive	
143	YES	NO	Negative	Negative	Negative	Positive					
147	YES	YES	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	
154	YES	YES	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	
157	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
159	YES	YES	Negative	Negative	Equivocal	Positive	Negative	Negative	Positive	Positive	
169	YES	YES	Negative	Positive	Positive	Positive	Negative	Positive	Positive	Positive	
181	YES	YES	Negative	Negative	Negative	Positive	Negative	Positive	Positive	Positive	
189	YES	NO	Negative	Negative	Negative	Negative					
190	YES	YES	Negative	Negative	Positive	Positive	Negative	Equivocal	Positive	Positive	
193	YES	YES	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	
194	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Weak Positive	Positive	
195	YES	YES	Negative	Negative	Negative	Positive	Negative	Positive	Positive	Positive	
197	YES	YES	NT	NT	NT	NT	NT	NT	NT	NT	No results returned
209	YES	YES	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	
216	YES	NO	Negative	Negative	Negative	Negative					
223	YES	YES	Negative	Positive	Positive	Positive	Negative	Positive	Positive	Positive	
229	YES	YES	Negative	Negative	Negative	Positive					
232	YES	NO	Negative	Negative	Negative	Positive					
238	YES	YES	Negative	Negative	Negative	Positive	Negative	Positive	Equivocal	Positive	Serum 3: Low cells and polynuclears
245	YES	YES	Negative	Negative	Positive	Positive	Negative	Equivocal	Positive	Positive	
252	YES	YES	Negative	Negative	Negative	Positive	Negative	Positive	Negative	Positive	
259	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
260	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
262	YES	YES	Negative	Negative	Negative	Positive	Negative	Positive	Positive	Positive	
292	YES	YES	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Positive	
293	YES	YES	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	
294	YES	YES	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	
297	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A02/2016 OS PC

DISPATCHED ON 02ND FEBRUARY 2016

Lab No.	PBL/T-cell without DTT				B-cell without DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
112	-1	4	6	8					90		
119	1	1	1	6					95		
120	1	1	1	4	1	4	6	8		100	100
128	1	1	1	4					95		
139	1	1	1	6	1	0	6	8	90	90	90
143	1	1	1	8					98		
147	1	1	1	6	1	2	4	8		95	90
154	1	1	1	2	1	1	4	6	95		
157	1	1	1	1	1	1	1	1	100	100	100
159	1	1	4	6	1	1	6	6		95	85
169	1	2	2	4	1	2	2	6		98	98
181	1	1	1	8	1	4	6	8		100	100
189	1	1	1	1					98		
190	5%	5%	20%	40%	10%	15%	40%	40%		95	60
193	1	1	2	4	1	1	4	6		99	95
194	1	1	1	1	1	1	4	6	100	99	85
195	1	1	1	4	1	6	6	8	90		85
197											
209				2			4	4	90		50
216	2	2	2	2					85		
223	1	4	6	8	2	6	8	8		85	85
229				4					90		
232				6					80		
238	1	1	1	4	1	8		8		95	80
245	1	1	2	4	1		6	8	100	100	100
252	1	1	1	4	1	4	1	4	60		50
259									15	15	15
260										90	90
262				4		6	8	8	80		
292						4	6	6		90	90
293				4			8	8		80	80
294	0	0	0	4	0	0	4	8		100	100
297	1	1	1	2	1	2	2	2	90	90	90

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A02/2016 OS PC

DISPATCHED ON 02ND FEBRUARY 2016

HLA PHENOTYPE OF BLOOD DONOR: HLA-A2, A29; B44, B62; Cw9, Cw16; DR1, DR15; DQ5, DQ6

	Summary of Results							
	PBL/T-Cells				B-Cells			
Total tested	26	26	25	25	20	18	18	20
Positive	0	1	2	17	0	1	10	16
Negative	26	25	23	8	20	17	8	4
NT/Equivocal	1	1	2	2	2	4	4	2
% Positive	0.0%	3.8%	8.0%	68.0%	0.0%	5.6%	55.6%	80.0%
% Negative	100.0%	96.2%	92.0%	32.0%	100.0%	94.4%	44.4%	20.0%
Consensus	Negative	Negative	Negative	Not Assessed	Negative	Negative	Not Assessed	Positive
HLA Antibody Specificity	DR17+	Cw4, Cw6	B14+	B8,B44,DR5,DR8 DR13	DR17+	Cw4, Cw6	B14+	B8,B44,DR5,DR8 DR13

(Defined By CDC)

Lab	PBL/T Cell	B Cell	With DTT				With DTT				
			Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
112	YES	NO	Negative	Negative	Negative	Positive					
119	YES	NO	Negative	Negative	Negative	Negative					
120	YES	YES	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	
139	YES	YES	Negative	Negative	Negative	Positive	Negative	Equivocal	Negative	Positive	
143	YES	NO	Negative	Negative	Negative	Weak Positive					
147	YES	YES	Negative	Negative	Negative	Positive	Negative	Negative	Equivocal	Positive	
157	NO	YES					Negative	Negative	Negative	Negative	
159	YES	YES	Negative	Negative	Equivocal	Positive	Negative	Negative	Positive	Positive	
169	YES	YES	Negative	Positive	Positive	Positive	Negative	Negative	Negative	Positive	
181	YES	YES	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	
189	YES	NO	Negative	Negative	Negative	Negative					
190	YES	YES	Negative	Negative	Negative	Positive	NT	NT	NT	NT	High cell death
193	YES	YES	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	
194	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Weak Positive	Positive	
195	YES	YES	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
197	YES	YES	NT	NT	NT	NT	NT	NT	NT	NT	No results returned
209	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
216	YES	NO	Negative	Negative	Negative	Negative					
229	YES	NO	Negative	Negative	Negative	Positive					
238	YES	YES	Negative	Negative	Negative	Positive	Negative	Negative	Equivocal	Positive	Serum 3: Low cells and polynuclears
245	YES	YES	Negative	Negative	Positive	Positive	Negative	Equivocal	Positive	Positive	
252	YES	YES	Negative	Negative	Negative	Positive	Negative	Positive	Negative	Positive	
260	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
262	YES	YES	Negative	Negative	Negative	Equivocal	Negative	Negative	Positive	Positive	
292	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	
293	YES	YES	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	
294	YES	YES	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	
297	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A02/2016 OS PC

DISPATCHED ON 02ND FEBRUARY 2016

Lab No.	PBL/T-cell with DTT				B-cell with DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
112	-1	-1	2	8					90		
119	1	1	1	1					95		
120	1	1	1	4	1	1	4	8		100	100
139	1	1	1	4	1	0	1	8	90	90	90
143	1	1	1	4						98	
147	1	1	1	6	1	1	2	8		95	90
157					1	1	1	1	100	100	100
159	1	1	4	4	1	1	4	6		95	85
169	1	2	2	4	1	1	1	6		98	98
181	1	1	1	8	1	1	6	8		100	100
189	1	1	1	1					98		
190	5%	5%	5%	20%	NT	NT	NT	NT		95	60
193	1	1	1	4	1	1	4	6		99	95
194	1	1	1	1	1	1	4	6	100	99	85
195	1	1	1	4	1	1	1	8	90		85
197											
209									90		50
216	2	2	2	2					85		
229				40%					90		
238	1	1	1	4	1	1		8		95	80
245	1	1	2	4	1		2	8	100	100	100
252	1	1	1	4	1	4	1	4	60		50
260										90	90
262							4	8	80		
292							6	6		90	90
293				4			8	8		80	80
294	0	0	0	4	0	0	6	8		100	100
297	1	1	1	1	1	1	1	2	90	90	90